Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

N/ACompletedNCT00195286

Wyeth is now a wholly owned subsidiary of Pfizer180 enrolled

Overview

The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections

Study Type

OBSERVATIONAL

Enrollment

180

Conditions

Urinary Infections

Interventions

piperacillin/tazobactamDRUG

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam. Exclusion Criteria: * Patients known, or thought to be hypersensitivity to beta-lactams * Patients with an uncomplicated urinary tract infection

Locations (27)

Unnamed facility

Antequera (Málaga), Spain

Unnamed facility

Ávila, Spain

Unnamed facility

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.